|
| [1]Benzothieno[2,3-b]pyridine-3-carboxamide, N-[4-(aminosulfonyl)phenyl]-1,2,5,6,7,8-hexahydro-4-hydroxy-2-oxo- Basic information |
Product Name: | [1]Benzothieno[2,3-b]pyridine-3-carboxamide, N-[4-(aminosulfonyl)phenyl]-1,2,5,6,7,8-hexahydro-4-hydroxy-2-oxo- | Synonyms: | [1]Benzothieno[2,3-b]pyridine-3-carboxamide, N-[4-(aminosulfonyl)phenyl]-1,2,5,6,7,8-hexahydro-4-hydroxy-2-oxo-;M435-1279;M435 1279,M4351279;4-Hydroxy-2-oxo-N-(4-sulfamoylphenyl)-1,2,5,6,7,8-hexahydrobenzo[4,5]thieno[2,3-b]pyridine-3-carboxamide | CAS: | 1359431-16-5 | MF: | C18H17N3O5S2 | MW: | 419.47 | EINECS: | | Product Categories: | | Mol File: | 1359431-16-5.mol | |
| [1]Benzothieno[2,3-b]pyridine-3-carboxamide, N-[4-(aminosulfonyl)phenyl]-1,2,5,6,7,8-hexahydro-4-hydroxy-2-oxo- Chemical Properties |
density | 1.620±0.06 g/cm3(Predicted) | storage temp. | Store at -20°C | pka | 4.50±1.00(Predicted) | form | Solid | color | White to off-white |
| [1]Benzothieno[2,3-b]pyridine-3-carboxamide, N-[4-(aminosulfonyl)phenyl]-1,2,5,6,7,8-hexahydro-4-hydroxy-2-oxo- Usage And Synthesis |
Biological Activity | M435-1279 is a UBE2T inhibitor. M435-1279 inhibits the Wnt/β-catenin signaling pathway hyperactivation through blocking UBE2T-mediated degradation of RACK1[1].
M435-1279 (0, 2, 4, 8, 16, 31 μM; 48 h) significantly inhibits the growth of HGC27, AGS, and MKN45 cells[1].M435-1279 (0, 4, 8, 12, 16, 20 μM) inhibits the cell viability with IC50s of 16.8, 11.88, 6.93, 7.76 μM of GES-1, HGC27, MKN45, AGS cells, respectively[1].M435-1279 (31 nM to 500 μM) binds to UBE2T with a KD value of 50.5 μM[1].M435-1279 (11.88 μM; 48 h) inhibits the ubiquitination of RACK1 and the hyperactivation of the Wnt/β-catenin pathway[1].
M435-1279 (5 mg/kg/day; intratumor injection for 18 days) slows the tumor growth[1].M435-1279 induces higher RACK1 proteins expression, and lower Ki-67 and β-catenin proteins expression in intratumor tumors[1]. | References | [1]. Yu Z, et al. A novel UBE2T inhibitor suppresses Wnt/β-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination. Oncogene. 2021 Feb;40(5):1027-1042. doi: 10.1038/s41388-020-01572-w. Epub 2020 Dec 15. Erratum in: Oncogene. 2021 Apr;40(14):2622-2623. |
| [1]Benzothieno[2,3-b]pyridine-3-carboxamide, N-[4-(aminosulfonyl)phenyl]-1,2,5,6,7,8-hexahydro-4-hydroxy-2-oxo- Preparation Products And Raw materials |
|